Daniel Frohwein, MD
Interventional Pain Medicine · Orlando, FLNPI 1760501266
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Amgen at 34.7% of the total. Reporting peaked in 2019 at $91 and has fallen 76.2% since, to $22 in 2024. That places this record below the midpoint for interventional pain medicine clinicians in FL, where the typical reported total is $4,625.
Across 15 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$111
- SPR Therapeutics, Inc$55
- Pacira Pharmaceuticals Incorporated$55
- Medtronic$36
- Boston Scientific$19
- Bioventus LLC$15
- plus $28 from 2 others
Across 1 payment — averaging $2351.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Stimlabs LLC$2K
What the payments were for
- Food & beverage$320100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $111 |
| SPR Therapeutics, Inc | 1 | $55 |
| Pacira Pharmaceuticals Incorporated | 3 | $55 |
| Medtronic | 1 | $36 |
| Boston Scientific | 1 | $19 |
| Bioventus LLC | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| Merck | 1 | $13 |
How this compares
$320 in reported general payments places this provider in the 10th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 111 | $1,637 |
| Morphine Sulfate ErMorphine Sulfate | 16 | $690 |
| Etodolac | 24 | $580 |
| Tizanidine Hcl | 37 | $309 |
| Baclofen | 12 | $145 |
| Methocarbamol | 21 | $133 |
| Celecoxib | 17 | $110 |
| Ibuprofen | 14 | $54 |
| Tramadol Hcl | 14 | $49 |
| Meloxicam | 15 | $40 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Orlando
- Richard GaylesOrlando$14K
- Louis RasoJupiter$1.3M
- Ajay AntonyGainesville$1.1M
- Michael EspositoVero Beach$777K
- Nomen AzeemRiverview$650K
- Stanley GolovacMerritt Island$367K
- Sunil PanchalLutz$363K
- Robert BallPort Charlotte$246K
- Justin MannJacksonville$243K
- Giuseppe PaeseBoca Raton$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.